SCHEMBL7606274

SCHEMBL7606274

CCn1nccc1NC=C1C(=O)Nc2nc(Cl)ccc21

nearest known ligand 0.31

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 1/20 0.31
DPP8 Q6V1X1 1/20 0.31
DPP9 Q86TI2 1/20 0.31
CCNK O75909 1/20 0.31
CDK12 Q9NYV4 1/20 0.31
MEN1 O00255 2/20 0.30
MAPT P10636 2/20 0.30
KMT2A Q03164 2/20 0.30
RECQL P46063 1/20 0.30
BLM P54132 1/20 0.30
GPR55 Q9Y2T6 1/20 0.30
IGF1R P08069 1/20 0.30
ALDH1A1 P00352 1/20 0.30
HPGD P15428 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30
NPSR1 Q6W5P4 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7606271 1.00 DPP4 (0.31) DPP4DPP8DPP9CCNKCDK12
SCHEMBL7605175 0.82 MAPT (0.44) CCNKCDK12MAPTIGF1RALDH1A1
SCHEMBL7605173 0.82 MAPT (0.44) CCNKCDK12MAPTIGF1RALDH1A1
SCHEMBL4862653 0.77 EGFR (0.46) MEN1MAPTKMT2AALDH1A1SMN1; SMN2
SCHEMBL4862659 0.77 EGFR (0.46) MEN1MAPTKMT2AALDH1A1SMN1; SMN2
SCHEMBL7614042 0.77 NTRK1 (0.41) CCNKCDK12
SCHEMBL7614047 0.77 NTRK1 (0.41) CCNKCDK12
SCHEMBL7606157 0.74 JAK3 (0.41) MEN1MAPTKMT2AALDH1A1HPGD
SCHEMBL7606158 0.74 JAK3 (0.41) MEN1MAPTKMT2AALDH1A1HPGD
SCHEMBL5434450 0.74 MAOA (0.43) MEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020099071-A1 Protein tyrosine kinase and protein serin/threonine kinase inhibitory activity; anticancer agents; treating chemotherapy induced alopecia GLENNON KIMBERLEY CAROLINE (US) 2002-07-25 US claimed
EP-1165514-A1 3-(ANILINOMETHYLENE) OXINDOLES AS PROTEIN TYROSINE KINASE AND PROTEIN SERINE/THREONINE KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2002-01-02 EP claimed
WO-2000056710-A1 3-(ANILINOMETHYLENE) OXINDOLES AS PROTEIN TYROSINE KINASE AND PROTEIN SERINE/THREONINE KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2000-09-28 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020099071-A1 Protein tyrosine kinase and protein serin/threonine kinase inhibitory activity; anticancer agents; treating chemotherapy induced alopecia PRKDC, PRKX, BMX DPP4 4390/4885DPP8 3560/4885DPP9 3604/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.